Clinical Trial Update: Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037) [Phase 3]

View source ↗

Summary

Phase 3 trial of preladenant in moderate to severe Parkinson's disease completed; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease
• Parkinson Disease

Drugs mentioned

• preladenant (preladenant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Parkinson Disease, Idiopathic Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2016-04-12